Sec Form 5 Filing - JORDEN DAVID EMERSON @ Nuo Therapeutics, Inc. - 2021-12-31

FORM 5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person JORDEN DAVID EMERSON 2. Issuer Name and Ticker or Trading Symbol Nuo Therapeutics, Inc. [ AURX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO/CFO (Last) (First) (Middle) C/O NUO THERAPEUTICS, INC., 8285 EL RIO, SUITE190 3. Date of Earliest Transaction (MM/DD/YY) 12/31/2021 (Street) HOUSTON, TX77054 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/30/2021 M 1,137,635 A $ 0.2 2,127,326 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants to purchase Common Stock $ 0.2 12/01/2021 A( 1 ) 1,297,635( 2 ) 12/01/2021 01/31/2022 Common Stock 1,297,635 $ 0( 3 ) 1,297,635 D Warrants to purchase Common Stock $ 0.4 12/01/2021 D( 1 ) 900,000( 4 ) 10/05/2020 10/05/2025 Common Stock 900,000 $ 0( 3 ) 0 D Warrants to purchase Common Stock $ 0.4 12/01/2021 D( 1 ) 397,635( 4 ) 10/05/2020 10/05/2025 Common Stock 397,635 $ 0( 3 ) 0 D Warrants to purchase Common Stock $ 0.4 12/06/2021 J( 5 ) 160,000 12/01/2021 01/31/2022 Common Stock 160,000 $ 0 1,137,635 D Warrants to purchase Common Stock $ 0.2 12/30/2021 M 1,137,635 12/01/2021 01/31/2022 Common Stock 1,137,635 $ 0( 3 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other JORDEN DAVID EMERSON C/O NUO THERAPEUTICS, INC. 8285 EL RIO, SUITE190 HOUSTON, TX77054 X CEO/CFO Signatures /s/ David Jorden 04/26/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Transaction approved by Board of Directors of Issuer and Non-Employee Directors ( 2 )Acquired in accordance with Warrant Modification Agreement dated as of 12/01/21 ( 3 )The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. ( 4 )Cancelled in accordance with Warrant Modification Agreement dated as of 12/01/21 ( 5 )Transferred to third party for no consideration

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.